Latest news
25 items- SECVBI Vaccines Inc. New filed SEC Form 8-K: Bankruptcy or Receivership, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits8-K - VBI Vaccines Inc/BC (0000764195) (Filer)
- PRVBI Vaccines Provides an Update on its Restructuring ProceedingsVBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided an update on the restructuring proceedings announced on July 30, 2024. U.S. Chapter 15 Filing On August 2, 2024, the United States Bankruptcy Court for the District of Delaware granted provisional relief under Chapter 15 of the U.S. Bankruptcy Code, and scheduled a further hearing to consider the recognition of the July 30, 2024, Ontario Superior Court of Justice (Commercial List) order ("Initial Order"), which granted the company protection under the Companies' Creditors Arrangement Act, R.S.C. 1985, c. C-36, as amended ("C
- SECVBI Vaccines Inc. New filed SEC Form 8-K: Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Other Events8-K - VBI Vaccines Inc/BC (0000764195) (Filer)
- PRVBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic AlternativesVBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the Ontario Superior Court of Justice (Commercial List) ("Court") has issued an initial order ("Initial Order") granting the company protection under the Companies' Creditors Arrangement Act, R.S.C. 1985, c. C-36, as amended ("CCAA"). The Initial Order provides for, among other things: (i) a stay of proceeding in favour of VBI, (ii) approval of the DIP Loan (as described below), and (iii) the appointment of Ernst & Young Inc. ("EY") to serve as monitor ("Monitor") in the Court during the restructuring ("Restructuring Pro
- SECVBI Vaccines Inc. New filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits8-K - VBI Vaccines Inc/BC (0000764195) (Filer)
- PRVBI Vaccines Announces Results of Annual General MeetingVBI Vaccines Inc. (NASDAQ:VBIV) ("VBI" or the "Company"), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the voting results from its annual general meeting of shareholders held on June 25, 2024 (the "Meeting"). The total number of common shares of the Company ("Common Shares") represented by shareholders ("Shareholders") present in person or represented by proxy at the Meeting was an aggregate of 13,879,327 Common Shares, representing 48.39% of VBI's issued and outstanding Common Shares as of the record date for the Meeting, April 26, 2024. The voting results with respect to each of the following eight dir
- NEWSVBI Vaccines Reports New Tumor Response Data From Ongoing Randomized Controlled Phase 2b Study Of VBI-1901 For Patients With Recurrent GlioblastomaAmong the 7 patients on VBI-1901 treatment long enough to have 1+ MRI scan at the time of analysis, one partial tumor response (PR) and two stable disease (SD) observations have occurred as of May 15, 2024The partial response, which demonstrated a 67% reduction in tumor size vs. baseline, was observed at week 6, after 2 doses of VBI-1901The disease control rate (DCR) in the VBI-1901 study arm was 43% (n=3/7) compared to 0% in the control arm (n=0/6) – n=5/6 patients in the control arm have experienced a 2-8x increase in tumor size vs. baseline and have been taken off study protocolFDA has granted both Fast Track Designation and Orphan Drug Designation to VBI-1901 in recurrent GBM following p
- SECVBI Vaccines Inc. New filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - VBI Vaccines Inc/BC (0000764195) (Filer)
- PRVBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma PatientsAmong the 7 patients on VBI-1901 treatment long enough to have 1+ MRI scan at the time of analysis, one partial tumor response (PR) and two stable disease (SD) observations have occurred as of May 15, 2024 The partial response, which demonstrated a 67% reduction in tumor size vs. baseline, was observed at week 6, after 2 doses of VBI-1901 The disease control rate (DCR) in the VBI-1901 study arm was 43% (n=3/7) compared to 0% in the control arm (n=0/6) – n=5/6 patients in the control arm have experienced a 2-8x increase in tumor size vs. baseline and have been taken off study protocol FDA has granted both Fast Track Designation and Orphan Drug Designation to VBI-1901 in recurrent G
- SECVBI Vaccines Inc. New filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - VBI Vaccines Inc/BC (0000764195) (Filer)
- NEWSVBI Vaccines To Present New Interim Phase 2b Data From VBI-1901 In Recurrent Glioblastoma Patients In Poster Presentation At 2024 ASCO Annual MeetingVBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company's cancer vaccine immunotherapeutic candidate in recurrent glioblastoma (GBM), were accepted for poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.The presentation at ASCO will provide an update to the encouraging data previously shared at the World Vaccine Congress Washington in April, including additional data from those initially evaluable patients, as well as data fro
- PRVBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma PatientsVBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company's cancer vaccine immunotherapeutic candidate in recurrent glioblastoma (GBM), were accepted for poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation at ASCO will provide an update to the encouraging data previously shared at the World Vaccine Congress Washington in April, including additional data from those initially evaluable patients, as well as data
- SECSEC Form 424B5 filed by VBI Vaccines Inc. New424B5 - VBI Vaccines Inc/BC (0000764195) (Filer)
- SECVBI Vaccines Inc. New filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - VBI Vaccines Inc/BC (0000764195) (Filer)
- SECSEC Form 10-Q filed by VBI Vaccines Inc. New10-Q - VBI Vaccines Inc/BC (0000764195) (Filer)
- NEWSVBI Vaccines Q1 EPS $(0.73) Up From $(3.22) YoY, Sales $1.21M Up From $485.00K YoYVBI Vaccines (NASDAQ:VBIV) reported quarterly losses of $(0.73) per share. This is a 77.33 percent increase over losses of $(3.22) per share from the same period last year. The company reported $1.21 million in sales this quarter. This is a 150.31 percent increase over sales of $485.00 thousand the same period last year.
- PRVBI Vaccines Reports First Quarter 2024 Financial ResultsPreHevbrio® (Hepatitis B Vaccine [Recombinant]) global net revenue increased 105% year-over-year in the first quarter of 2024 compared to the first quarter of 2023 Initial encouraging tumor response data from randomized Phase 2b study of VBI-1901 in recurrent glioblastoma (GBM) announced in April – additional data expected mid-year and year-end 2024 Evaluation of novel mRNA-launched eVLP (MLE) platform technology underway by potential partners VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the quarter ended M
- SECVBI Vaccines Inc. New filed SEC Form 8-K: Other Events8-K - VBI Vaccines Inc/BC (0000764195) (Filer)
- SECSEC Form ARS filed by VBI Vaccines Inc. NewARS - VBI Vaccines Inc/BC (0000764195) (Filer)
- SECSEC Form DEFA14A filed by VBI Vaccines Inc. NewDEFA14A - VBI Vaccines Inc/BC (0000764195) (Filer)
- SECSEC Form DEF 14A filed by VBI Vaccines Inc. NewDEF 14A - VBI Vaccines Inc/BC (0000764195) (Filer)
- 13D/GSEC Form SC 13D/A filed by VBI Vaccines Inc. New (Amendment)SC 13D/A - VBI Vaccines Inc/BC (0000764195) (Subject)
- SECSEC Form 10-K filed by VBI Vaccines Inc. New10-K - VBI Vaccines Inc/BC (0000764195) (Filer)
- SECVBI Vaccines Inc. New filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - VBI Vaccines Inc/BC (0000764195) (Filer)
- PRVBI Vaccines Reports Full Year 2023 Financial ResultsPreHevbrio® (Hepatitis B Vaccine [Recombinant]) global net revenue increased 234% year-over-year from 2022 to 2023 Preliminary 2024 PreHevbrio U.S. sales demonstrate continued growth, with approximately 65% of 2023 full-year volume sold in Q1 2024 alone Early data from randomized Phase 2b study of VBI-1901 in recurrent glioblastoma (GBM) demonstrate encouraging separation of tumor response trends between VBI-1901 study arm and standard-of-care arm Upcoming milestones across lead pipeline programs include: Additional interim data readouts from randomized, controlled Phase 2b study of VBI-1901 in recurrent GBM expected mid-year and year-end 2024 Evaluation of novel mRNA-launche
VBIV FAQ
6 questionsWhat does VBI Vaccines Inc. New do?
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma...Where does VBIV stock trade?
VBI Vaccines Inc. New (VBIV) is listed on NASDAQ.What sector and industry is VBIV in?
VBI Vaccines Inc. New operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about VBIV?
VBI Vaccines Inc. New has had 3 recent analyst actions on file. The most recent action was from Raymond James: Outperform with a $200.00 price target on 2022-11-11. Recent price targets range from $200.00 to $600.00.What companies are similar to VBIV?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare VBIV side-by-side with any of them on Quantisnow.How can I track VBIV on Quantisnow?
Quantisnow aggregates VBI Vaccines Inc. New's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VBIV to receive live email and push alerts on every new disclosure.